Clinical Trials

Date: 2015-09-19

Type of information: Presentation of results at a congress

phase: preclinical

Announcement: presentation of results at the 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC)

Company: Melinta Therapeutics (USA - CT)

Product: delafloxacin

Action mechanism:

antibiotic. Delafloxacin is an investigational anionic fluoroquinolone antibiotic currently in Phase 3 clinical development for hospital-treated skin infections, known as acute bacterial skin and skin structure infections (ABSSSI).
In clinical trials, delafloxacin is being tested in both IV and oral formulations.

Disease:

Therapeutic area: Infectious diseases

Country:

Trial details:

Latest news:

• On September 19, 2015, Melinta Therapeutics announced in vitro results demonstrating delafloxacin’s activity against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, three bacteria commonly associated with respiratory tract infections. Complete results from this study have been presented at the 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC).
In this study, delafloxacin was tested against more than 500 S. pneumoniae, H. influenzae and M. catarrhalis isolates from around the United States and Europe, including S. pneumoniae isolates that had shown resistance to levofloxacin, penicillin and ceftriaxone.
Delafloxacin’s activity was compared to antibiotics covering multiple classes including the currently marketed quinolones ciprofloxacin, levofloxacin and moxifloxacin. Among these antibiotics, delafloxacin was the most potent compound tested against S. pneumoniae, H. influenza and M. catarrhalis. Importantly, delafloxacin was shown to be active against all resistant S. pneumoniae isolates and was not affected by beta-lactamase status in H. influenza and M. catarrhalis.